AccuraGen Appoints George Cardoza as Chief Executive Officer
AccuraGen, a leading precision oncology company, working on approaches to improve sensitivity and performance of liquid biopsy for tumor profiling and the detection of early-stage cancers, is pleased to announce that George Cardoza will be joining AccuraGen as its Chief Executive Officer and will also be joining the Board of Directors; Dr. Kang Ying, co-founder and angel investor of the Company, will be stepping down as CEO, but will remain as the Chairman of the Board and continue to serve the Company. “It is my pleasure to welcome George, who brings many years of experience in launching clinical tests that benefit patients. I’m glad to see our technology being expanded globally and used on multiple applications along a patient journey.” Dr Ying said.
George Cardoza comes to the firm having spent over 14 years with Quest Diagnostics and 12 with NeoGenomics Laboratories. He previously held the positions of Chief Financial Officer, President Pharma Services Division and Chief Operating Officer and President of Laboratory Operations at NeoGenomics. Mr. Cardoza said “I’m honored and excited to be the new CEO of AccuraGen. I’m looking forward to working with the teams in both United States and China. I’ve been extremely impressed by the teams and the technology that they have developed as the Company is a hidden gem. AccuraGen’s platform can be used by laboratories around the world to improve patient care.”
“We are thrilled to have George join AccuraGen as CEO and lead us into the next phase for the company. We also are grateful to Kang for his contribution as CEO and look forward to continuing to work closely with him in China and at the Board,” said Dan Zabrowski, Board Member of AccuraGen and Venture Partner, Decheng Capital.
Liquid biopsy assays have grown rapidly in recent years, particularly for cancers such as lung cancer where tissue is difficult to obtain, and quantities are limited. Liquid biopsy assays are also increasingly being used in conjunction with tissue analysis as they have broader coverage than a single piece of tissue. AccuraGen has developed a liquid biopsy platform that utilizes unique biochemistry and machine learning to extract a variety of cancer signals in plasma. The platform provides new dimensions in treatment guidance, minimal residue disease detection and early screening. Inquiries about AccuraGen can be directed to email@example.com
AccuraGen aims to revolutionize cancer management through technology innovation in molecular testing. AccuraGen focuses on the analysis of highly fragmented circulating nucleic acid in blood and has developed proprietary technologies enabling superior performance in the analysis of genomic, epigenetic, and RNA changes.
AccuraGen is headquartered in San Jose, California, USA with CAP-accredited facility in Shanghai, China.